PMC:7601109 / 671-979 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T6","span":{"begin":29,"end":39},"obj":"Disease"}],"attributes":[{"id":"A6","pred":"mondo_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/MONDO_0006516"}],"text":"nhealthy patterns of eating. Sarcopenia has multiple detrimental effects including falls, hospitalization, disability, and institutionalization. Although a few pharmacological agents (e.g., bimagrumab, sarconeos, and exercise mimetics) are being explored in different stages of trials, not a single drug has "}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T96306","span":{"begin":40,"end":43},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T81360","span":{"begin":154,"end":155},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T83052","span":{"begin":290,"end":291},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T91336","span":{"begin":304,"end":307},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"}],"text":"nhealthy patterns of eating. Sarcopenia has multiple detrimental effects including falls, hospitalization, disability, and institutionalization. Although a few pharmacological agents (e.g., bimagrumab, sarconeos, and exercise mimetics) are being explored in different stages of trials, not a single drug has "}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T1","span":{"begin":299,"end":303},"obj":"Chemical"}],"attributes":[{"id":"A1","pred":"chebi_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"}],"text":"nhealthy patterns of eating. Sarcopenia has multiple detrimental effects including falls, hospitalization, disability, and institutionalization. Although a few pharmacological agents (e.g., bimagrumab, sarconeos, and exercise mimetics) are being explored in different stages of trials, not a single drug has "}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T39259","span":{"begin":21,"end":27},"obj":"http://purl.obolibrary.org/obo/GO_0007631"}],"text":"nhealthy patterns of eating. Sarcopenia has multiple detrimental effects including falls, hospitalization, disability, and institutionalization. Although a few pharmacological agents (e.g., bimagrumab, sarconeos, and exercise mimetics) are being explored in different stages of trials, not a single drug has "}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T1","span":{"begin":83,"end":88},"obj":"Phenotype"}],"attributes":[{"id":"A1","pred":"hp_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/HP_0002527"}],"text":"nhealthy patterns of eating. Sarcopenia has multiple detrimental effects including falls, hospitalization, disability, and institutionalization. Although a few pharmacological agents (e.g., bimagrumab, sarconeos, and exercise mimetics) are being explored in different stages of trials, not a single drug has "}

{"project":"LitCovid-sentences","denotations":[{"id":"T7","span":{"begin":29,"end":144},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"nhealthy patterns of eating. Sarcopenia has multiple detrimental effects including falls, hospitalization, disability, and institutionalization. Although a few pharmacological agents (e.g., bimagrumab, sarconeos, and exercise mimetics) are being explored in different stages of trials, not a single drug has "}

{"project":"LitCovid-PubTator","denotations":[{"id":"34","span":{"begin":190,"end":200},"obj":"Chemical"},{"id":"43","span":{"begin":29,"end":39},"obj":"Disease"}],"attributes":[{"id":"A34","pred":"tao:has_database_id","subj":"34","obj":"MESH:C000596367"},{"id":"A43","pred":"tao:has_database_id","subj":"43","obj":"MESH:D055948"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"nhealthy patterns of eating. Sarcopenia has multiple detrimental effects including falls, hospitalization, disability, and institutionalization. Although a few pharmacological agents (e.g., bimagrumab, sarconeos, and exercise mimetics) are being explored in different stages of trials, not a single drug has "}